No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 12, 2013, Pages 976-985

  De Kam, Pieter Jan ^a   El Galta, Rachid ^b   Kruithof, Annelieke C ^c   Fennema, Hein ^b   Van Lierop, Marie José ^b   Mihara, Katsuhiro ^b   Burggraaf, Jacobus ^c   Moerland, Matthijs ^c   Peeters, Pierre ^b,c   Troyer, Matthew D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD   (Netherlands)

^c CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Aspirin; Coagulation; Safety; Sugammadex

Indexed keywords

ACETYLSALICYLIC ACID; ACTAVIS; PLACEBO; SUGAMMADEX; UNCLASSIFIED DRUG;

ADULT; ALLERGIC REACTION; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; URTICARIA;

ADOLESCENT; ADULT; ASPIRIN; BLOOD COAGULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GAMMA-CYCLODEXTRINS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION;

EID: 84891321960     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201970     Document Type: Article

References (22)

1. Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, Palin R, Prosser A, Rees DC, Rosair GM, Stevenson D, Tarver GJ, Zhang MQ. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem. 2002; 45: 1806-1816. CrossRef PubMed
2. Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002; 41: 266-270. PubMed
3. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008; 109: 816-824. CrossRef PubMed
4. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010; 27: 874-881. CrossRef PubMed
5. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010; 110: 64-73. CrossRef PubMed
6. Lemmens HJ, El-Orbany MI, Berry J, Morte JB Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010; 10: 15. CrossRef PubMed
7. Rahe-Meyer N, Schulman S, Klimscha W, Przemeck M, Blobner M, Wulf HF, Fennema H. Sugammadex reversal of rocuronium- or vecuronium-induced neuromuscular blockade is not associated with an increased risk of either bleeding or blood loss compared with usual care. Abstract submitted to: The International Anesthesia Research Society (IARS) Annual Meeting 2013, San Diego, California.
8. Soni A. Aspirin use among the Adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. Statistical brief #179. July 2007. Agency for Healthcare Research and Quality, Rockville, Md. Available from: URL: http://meps.ahrq.gov/mepsweb/data-files/publications/st179/stat179. pdf [Accessed 2013 February 11].
9. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006; 30: 74-77. CrossRef PubMed
10. Moerland M, Kemme MJ, van der Linden M, Burggraaf J. Measurement of collagen- and serotonininduced platelet aggregation in whole blood. Expert Rev Clin Pharmacol. 2010; 3: 177-182. CrossRef PubMed
11. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353: 2373-2383. CrossRef PubMed
12. Caplain H. Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers. Cerebrovasc Dis. 2005; 19: 214-219. CrossRef PubMed
13. Yokoyama T, Yamasaki F, Yamashita K, Manabe M, Suwa K. Bleeding time prolonged by daily low-dose aspirin is shortened by one medium dose aspirin. Acta Anaesthesiol Scand. 2008; 52: 1226-1230. CrossRef PubMed
14. Koster T, Caekebeke-Peerlinck KM, Briet E. A randomized and blinded comparison of the sensitivity and the reproducibility of the Ivy and Simplate II bleeding time techniques. Am J Clin Pathol. 1989; 92: 315-320. PubMed
15. de Zwart MA, ten Bruggencate-Broeders J, van Hal HJ, Megens RH, Frasa HW. Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879: 1573-1586. CrossRef PubMed
16. Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S. Ex vivo - in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A. Clin Pharmacol Ther. 2000; 67: 305-313. CrossRef PubMed
17. Saha S, Berglund M, Sylvén C, Gordon A, Agewall S. Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. Int J Cardiol. 2008; 123: 195-196. CrossRef PubMed
18. Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation. 1997; 96: 3860-3866. CrossRef PubMed
19. de Kam P-J, El Galta R, van Lierop M-J, Dennie J, Burggraaf J, Kruithof A, Troyer M. Sugammadex (4 mg/kg or 16 mg/kg) has no clinically relevant interaction effects on anticoagulant activity of enoxaparin or unfractionated heparin. Abstract submitted to: The International Anesthesia Research Society (IARS) Annual Meeting 2013, San Diego, California.
20. Zupan IP, Šabovič M, Salobir B, Ponikvar JB, Černelč P. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis. 2003; 42: 746-751. CrossRef PubMed
21. Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost. 2010; 36: 34-40. CrossRef PubMed
22. Lichtenthal PR, Rossi EC, Louis G, Rehnberg KA, Wade LD, Michaelis LL, Fung HL, Patrignani P. Dose-related prolongation of the bleeding time by intravenous nitroglycerin. Anesth Analg. 1985; 64: 30-33. CrossRef PubMed